Akebia Therapeutics, Inc. (AKBA)

Akebia Therapeutics Stock Forecast

Stock Price Forecast

The 6 analysts that cover Akebia Therapeutics stock have a consensus rating of "Strong Buy" and an average price target of $6.25, which forecasts a 285.80% increase in the stock price over the next year. The lowest target is $5.00 and the highest is $7.50.

Price Target: $6.25 (+285.80%)

Analyst Consensus: Strong Buy

Target	Low	Average	Median	High
Price	$5.00	$6.25	$6.00	$7.50
Change	+208.64%	+285.80%	+270.37%	+362.96%

Analyst Ratings

The average analyst rating for Akebia Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating	Jul '25	Aug '25	Sep '25	Oct '25	Nov '25	Dec '25
Strong Buy	3	3	3	4	4	4
Buy	2	2	2	2	2	2
Hold	0	0	0	0	0	0
Sell	0	0	0	0	0	0
Strong Sell	0	0	0	0	0	0
Total	5	5	5	6	6	6

Latest Forecasts

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Julian Harrison BTIG	BTIG	Strong Buy Reiterates $5	Strong Buy	Reiterates	$5	+208.64%	Dec 2, 2025
Matthew Caufield HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Reiterates $6	Strong Buy	Reiterates	$6	+270.37%	Dec 2, 2025
Matthew Caufield HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Maintains $8 → $6	Strong Buy	Maintains	$8 → $6	+270.37%	Oct 30, 2025
Julian Harrison BTIG	BTIG	Strong Buy Maintains $10 → $5	Strong Buy	Maintains	$10 → $5	+208.64%	Oct 29, 2025
Matthew Caufield HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $8	Strong Buy	Initiates	$8	+393.83%	Jun 4, 2025

More Analyst Ratings

Financial Forecast

Revenue This Year

244.09M

Increased by 52.38%

from 160.18M

Revenue Next Year

298.89M

Increased by 22.45%

from 244.09M

EPS This Year

0.04

from -0.33

EPS Next Year

0.13

Increased by 189.77%

from 0.04

Fiscal Year	FY 2020	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	FY 2026
Period Ending	Dec 31, 2020	Dec 31, 2021	Dec 31, 2022	Dec 31, 2023	Dec 31, 2024	Dec 31, 2025	Dec 31, 2026
Revenue	294.64M	211.65M	292.48M	194.62M	160.18M	244.09M	298.89M
Revenue Growth	-12.05%	-28.17%	38.19%	-33.46%	-17.70%	52.38%	22.45%
EPS	-2.78	-1.70	-0.52	-0.28	-0.33	0.04	0.13
EPS Growth	-	-	-	-	-	-	189.77%
Forward PE	-	-	-	-	-	36.10	12.46
No. Analysts	-	-	-	-	-	7	7

Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue	2025	2026	2027	2028	2029	2030
High	267.1M	329.2M
Avg	244.1M	298.9M
Low	219.5M	252.8M

Revenue Growth

Revenue Growth	2025	2026	2027	2028	2029	2030
High	66.8%	34.9%
Avg	52.4%	22.5%
Low	37.0%	3.6%

EPS Forecast

EPS	2025	2026	2027	2028	2029	2030
High	0.12	0.29
Avg	0.04	0.13
Low	-0.03	-0.06

EPS Growth

EPS Growth	2025	2026	2027	2028	2029	2030
High	-	555.1%
Avg	-	189.8%
Low	-	-

Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.